



Date: 3 May 2018

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office
and

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

NOXOPHARM CEO INTERVIEW ON NEAR-COMplete NOX66 CHEMOTHERAPY TRIAL

Sydney, 3 May 2018: Noxopharm (ASX: NOX) today releases the second of a series of 3 interviews with CEO, Dr Graham Kelly. The interviews with the Finance News Network provide an update on each of the 3 general NOX66 programs:

- NOX66 as an enhancer of radiotherapy
- NOX66 as an enhancer of the efficacy and safety of chemotherapy
- The supporting R&D program.

The second interview in the series looks at the the near-completed NOX66 and chemotherapy (CEP-1) clinical study and explains why the Company sees it as an important component of its overall clinical strategy.

This interview can be found by visiting the Noxopharm website Investors / Presentation page at www.noxopharm.com

.....

About the CEP Program (Chemo-Enhancement Program).

This program is using NOX66 to enhance the anti-cancer effect of certain common chemotherapy drugs in order for those drugs to be used at dosages generally considered to be sub-optimal in terms of anti-cancer activity, but associated with fewer side-effects. Commonly-used chemotherapy drugs such as cisplatin, carboplatin, paclitaxel and vincristine are associated with significant side-effects. Some of those side-effects such as nausea, vomiting and hair loss last only for the duration of treatment, while others such as bone marrow depression (low red and white blood cell levels) and nerve damage (peripheral neuropathy, ototoxicity) can persist for long periods post-treatment and be significantly debilitating. The CEP program is seeking to use NOX66

to minimise or even avoid the worst of these side-effects, without compromising the anti-cancer effect of the chemotherapy. Achieving this objective could represent a major step forward in the use of chemotherapy.

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour. The radio-enhancing effects of idronoxil are believed to involve at least 2 functions: (i) its ability to block DNA repair mechanisms (PARP-1, topoisomerases 1 and 2); (ii) its immune-enhancing effects, stimulating the activity of human natural killer (NK) cells.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product, with later generation drug candidates under development.

Investor & Corporate Enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 9299 9690

E: dfranks@fa.com.au

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.